WeVote
Log In

Bill

Bill

HB 3686

Relating to a special election; declaring an emergency.

2025 Regular Session Introduced by Werner Reschke

GnRH-analog–containing compounds are added to Illinois Schedule V, subjecting them to the same regulatory controls as other Schedule V substances.

In committee upon adjournment.
0
WeVote Research Nonpartisan
Bill Summary · HB 3686

Summary — HB 3686 (CONT SUB-PUB BLOCKER-SCH V)

Status: Enacted by Governor (signed 2025-06-20); effective 2025-09-01
Introduced: 02/18/2025 by Rep. Tom Weber
Statute amended: Illinois Controlled Substances Act, 720 ILCS 570/212 (Schedule V)

Purpose

HB 3686 amends the Illinois Controlled Substances Act to add compounds that contain gonadotropin-releasing hormone (GnRH) analogs to Schedule V of controlled substances. The change formally subjects such compounds to the regulatory controls that apply to Schedule V substances under Illinois law.

Key provisions

  • Amends Section 212 of the Illinois Controlled Substances Act (720 ILCS 570/212).
  • Inserts a new subsection (f) (in the bill’s text) specifying: any compound containing gonadotropin-releasing hormone analogs is a Schedule V controlled substance.
  • The amendment places GnRH-analog–containing compounds alongside other Schedule V listings (e.g., low-dose codeine mixtures, pregabalin, lacosamide, pyrovalerone, certain methamphetamine precursors).

Who or what is affected

  • Patients receiving GnRH analogs (commonly used clinically for conditions such as prostate cancer, endometriosis, uterine fibroids, central precocious puberty, and some other endocrine conditions) — their medications will be classified as controlled substances under Schedule V.
  • Prescribers (physicians, advanced practice nurses, physician assistants) who prescribe GnRH-analog therapies.
  • Pharmacies, hospital pharmacies, and dispensing practitioners who will need to comply with Schedule V handling, recordkeeping, and dispensing rules.
  • Manufacturers, wholesalers, and compounding pharmacies that produce or distribute GnRH-analog preparations.
  • Law enforcement and regulatory agencies administering controlled substances rules.

Practical implications

  • Classification as Schedule V subjects these compounds to the Controlled Substances Act’s regulatory regime (registration, recordkeeping, controlled dispensing practices and potential criminal/administrative penalties for unauthorized distribution or possession).
  • Patients may see changes in prescription handling (e.g., different dispensing procedures or documentation). The bill does not itself change clinical indications, dosing, or insurance coverage but could affect access logistics.
  • Healthcare entities and suppliers will need to update compliance procedures and may need to register or modify existing controlled-substance protocols.

Legislative and timeline notes

  • Bill introduced 02/18/2025. Passed both chambers in May 2025 (House and Senate actions recorded 05/06–05/28/2025), enrolled 05/30/2025, signed by Governor 06/20/2025.
  • Statutory effective date: September 1, 2025.

Statutory citation (as amended)

  • 720 ILCS 570/212 — new provision adding: “Any compound containing gonadotropin-releasing hormone analogs.”

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.